Novo Nordisk’s blockbuster diabetes drug is set to reshape India’s pharma market as the semaglutide patent expiry approaches. More than 50 companies are preparing generic versions, triggering a major race in the obesity and diabetes drug segment.
Aurobindo Pharma’s subsidiary, Eugia Pharma, has launched Pomalidomide Capsules in the U.S., targeting the $3.3?billion oncology and specialty drug market.
Glenmark plans to launch affordable semaglutide in India, competing with major players like Sun Pharma and Dr. Reddy’s. Aiming to revolutionize the anti-diabetes market.
Sai Life Sciences is gaining momentum as India’s pharma boom drives demand for drug development and manufacturing services, posting strong revenue and profit growth in 2026.
.png)
India has reopened the Pharma PLI scheme for select bulk drugs, giving manufacturers another chance to secure incentives and scale up domestic API production.
Sanofi Consumer Healthcare India has posted impressive financial results for Q4’25, with a 50% jump in profit after tax (PAT) and a 47% rise in revenue. For the full year, the company achieved a 21% growth in revenue, delivering strong performance ac
Zydus Lifesciences is preparing a day-one launch of its semaglutide generic in India after patent expiry in March 2026. The drug will be sold as Semaglyn, Mashema, and Altreme with a reusable multi-dose pen.
Akums Drugs & Pharmaceuticals Ltd. has secured EU GMP certification for two India plants and entered the UK market with MHRA approval for Rivaroxaban, strengthening its push into regulated European markets.
Morepen Laboratories has secured a Rs 825 crore multi-year CDMO contract from a global pharmaceutical company, marking one of its largest mandates and reinforcing its growing presence in global manufacturing partnerships.
Lonza expands Advanced Synthesis to accelerate ADC and bioconjugate development, integrating GlycoConnect, HydraSpace, dual-payload technology, and scalable CDMO services.
.jpg)
, CDSCO.jpg)